These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36135712)

  • 21. Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
    Ligorio F; Lobefaro R; Fucà G; Provenzano L; Zanenga L; Nasca V; Sposetti C; Salvadori G; Ficchì A; Franza A; Martinetti A; Sottotetti E; Formisano B; Depretto C; Scaperrotta G; Belfiore A; Vingiani A; Ferraris C; Pruneri G; de Braud F; Vernieri C
    Int J Cancer; 2024 Jan; 154(1):114-123. PubMed ID: 37615485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
    Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
    Geyer CE; Sikov WM; Huober J; Rugo HS; Wolmark N; O'Shaughnessy J; Maag D; Untch M; Golshan M; Lorenzo JP; Metzger O; Dunbar M; Symmans WF; Rastogi P; Sohn JH; Young R; Wright GS; Harkness C; McIntyre K; Yardley D; Loibl S
    Ann Oncol; 2022 Apr; 33(4):384-394. PubMed ID: 35093516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
    Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
    Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.
    Yang R; Shi YY; Han XH; Liu S
    Oncol Res Treat; 2021; 44(6):333-343. PubMed ID: 33975311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer.
    Li C; Rich B; Bullock JM; Barrière O; Marier JF; Beelen A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1067-1079. PubMed ID: 36180417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
    Daniel D; Kuchava V; Bondarenko I; Ivashchuk O; Reddy S; Jaal J; Kudaba I; Hart L; Matitashvili A; Pritchett Y; Morris SR; Sorrentino JA; Antal JM; Goldschmidt J
    Int J Cancer; 2021 May; 148(10):2557-2570. PubMed ID: 33348420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
    de Pádua Souza C; Carneiro ASB; de Oliveira Lessa AC; Lacerda DC; Paiva CE; Zorzetto MMC; de Freitas AJA; Santana IVV; de Oliveira MA; Palmero EI; Marques MMC; Reinert T
    Breast Cancer Res Treat; 2023 Nov; 202(1):57-65. PubMed ID: 37578666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
    Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
    Kuemmel S; Campone M; Loirat D; Lopez RL; Beck JT; De Laurentiis M; Im SA; Kim SB; Kwong A; Steger GG; Adelantado EZ; Duhoux FP; Greil R; Kuter I; Lu YS; Tibau A; Özgüroğlu M; Scholz CW; Singer CF; Vega E; Wimberger P; Zamagni C; Couillebault XM; Fan L; Guerreiro N; Mataraza J; Sand-Dejmek J; Chan A
    Clin Cancer Res; 2022 Jan; 28(1):106-115. PubMed ID: 34615719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
    Pellegrino B; Cavanna L; Boggiani D; Zamagni C; Frassoldati A; Schirone A; Caldara A; Rocca A; Gori S; Piacentini F; Berardi R; Brandes AA; Foglietta J; Villa F; Todeschini R; Tognetto M; Naldi N; Bortesi B; Montemurro F; Ardizzoni A; Boni L; Musolino A
    ESMO Open; 2021 Feb; 6(1):100019. PubMed ID: 33399082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    Gluz O; Nitz U; Liedtke C; Christgen M; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Bangemann N; Lindner C; Kuemmel S; Clemens M; Potenberg J; Staib P; Kohls A; von Schumann R; Kates R; Kates R; Schumacher J; Wuerstlein R; Kreipe HH; Harbeck N
    J Natl Cancer Inst; 2018 Jun; 110(6):628-637. PubMed ID: 29228315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
    Lobefaro R; Mariani L; Peverelli G; Ligorio F; Fucà G; Rametta A; Zattarin E; Leporati R; Presti D; Cantarelli B; Depretto C; Vingiani A; Manoukian S; Scaperrotta G; Bianchi GV; Capri G; Pruneri G; de Braud F; Vernieri C
    Clin Breast Cancer; 2023 Apr; 23(3):e151-e162. PubMed ID: 36599769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
    Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
    JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.